JPRN-jRCT2080221969未知2 期
A Phase 2, Open-label, Single-arm Study of TAK-700 (orteronel) in Patients With Nonmetastatic Castration-resistant Prostate Cancer and Rising Prostate-specific Antigen
试验速览
- 阶段
- 2 期
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
- •- No radiographic evidence of metastasis confirmed
- •- PSA rising defined as the following: increase in PSA
- •- Prior surgical castration or concurrent use of an agent for medical castration
- •- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
排除标准
- •- Received prior chemotherapy for prostate cancer
- •- Current spinal cord compression, bilateral hydronephrosis or current bladder neck outlet obstruction
- •- Uncontrolled cardiovascular condition as specified in study protocol
- •- Uncontrolled nausea, vomiting or diarrhea
研究者
相似试验
进行中（未招募）
1 期
Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castrationMedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002122-67-BEEORTC200
进行中（未招募）
不适用
Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration.EUCTR2012-002122-67-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)200
进行中（未招募）
不适用
Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castrationMedDRA version: 16.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002122-67-ITEORTC200
未知
3 期
Open-label study of TAK-875Diabetes mellitusJPRN-jRCT2080221565TAKEDA PHARMACEUTICAL COMPANY LTD.
已完成
1 期
Safety Study of TAK-700 in Subjects With Prostate Cancer.Prostatic NeoplasmsNCT00569153Millennium Pharmaceuticals, Inc.123